A detailed history of Nuveen Asset Management, LLC transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 55,922 shares of PBYI stock, worth $144,278. This represents 0.0% of its overall portfolio holdings.

Number of Shares
55,922
Holding current value
$144,278
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$2.92 - $5.83 $163,292 - $326,025
55,922 New
55,922 $182,000
Q2 2022

Aug 15, 2022

SELL
$1.64 - $3.3 $163,322 - $328,637
-99,587 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$2.13 - $3.24 $55 - $84
26 Added 0.03%
99,587 $308,000
Q4 2021

Feb 14, 2022

SELL
$2.85 - $6.58 $27,667 - $63,878
-9,708 Reduced 8.88%
99,561 $283,000
Q3 2021

Nov 12, 2021

SELL
$6.63 - $9.39 $14,155 - $20,047
-2,135 Reduced 1.92%
109,269 $754,000
Q2 2021

Aug 16, 2021

SELL
$8.98 - $11.6 $1.19 Million - $1.54 Million
-132,963 Reduced 54.41%
111,404 $1.02 Million
Q1 2021

May 17, 2021

BUY
$9.38 - $13.63 $965,361 - $1.4 Million
102,917 Added 72.76%
244,367 $2.38 Million
Q4 2020

Feb 16, 2021

BUY
$7.78 - $12.13 $2,077 - $3,238
267 Added 0.19%
141,450 $1.45 Million
Q3 2020

Nov 16, 2020

SELL
$9.5 - $11.14 $2.94 Million - $3.45 Million
-309,957 Reduced 68.71%
141,183 $1.42 Million
Q2 2020

Aug 14, 2020

SELL
$7.01 - $13.24 $198,999 - $375,857
-28,388 Reduced 5.92%
451,140 $4.71 Million
Q1 2020

May 14, 2020

SELL
$6.28 - $14.57 $5.03 Million - $11.7 Million
-800,760 Reduced 62.55%
479,528 $4.05 Million
Q4 2019

Feb 14, 2020

BUY
$6.5 - $10.73 $767,305 - $1.27 Million
118,047 Added 10.16%
1,280,288 $11.2 Million
Q3 2019

Nov 14, 2019

BUY
$8.75 - $12.85 $4.86 Million - $7.13 Million
555,116 Added 91.43%
1,162,241 $12.5 Million
Q2 2019

Aug 15, 2019

BUY
$12.3 - $35.76 $7.47 Million - $21.7 Million
607,125 New
607,125 $7.72 Million

Others Institutions Holding PBYI

About PUMA BIOTECHNOLOGY, INC.


  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $118M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.